×
Choose Speciality

EXPLORE!

LOGIN

Updates on Secukinumab

  986 Views

Dr Chandrashekhar BS, Bengaluru    21 January 2019

  • IL-17 plays a significant role in the immune-pathogenesis of psoriasis.
  • Secukinumab is a fully human monoclonal IgG1-k antibody that selectively binds to and inhibits IL-17A, preventing binding to the IL-17 receptor. Secukinumab, an IL-17 inhibitor, was approved in US: 2015 for moderate-to-severe plaque psoriasis; 2016 for psoriatic arthritis (PsA) and ankylosing spondylitis.
  • FDA approval of secukinumab for moderate-to-severe plaque psoriasis. The updated label includes Secukinumab data in moderate-to-severe scalp psoriasis-one of the difficult to treat forms of the disease, which affects approximately half of all psoriasis patients.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.